Edition:
United Kingdom

Nymox Pharmaceutical Corp (NYMX.OQ)

NYMX.OQ on NASDAQ Stock Exchange Capital Market

3.78USD
23 May 2018
Change (% chg)

$0.01 (+0.27%)
Prev Close
$3.77
Open
$3.79
Day's High
$3.85
Day's Low
$3.73
Volume
14,444
Avg. Vol
42,359
52-wk High
$4.67
52-wk Low
$3.00

Chart for

About

Nymox Pharmaceutical Corp is a Canada-based biopharmaceutical company. The Company is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. The Company operates through the research and development of products for the... (more)
No analyst recommendations are available for .

Overall

Beta: 0.85
Market Cap(Mil.): $200.04
Shares Outstanding(Mil.): 52.37
Dividend: --
Yield (%): --

Financials

  NYMX.OQ Industry Sector
P/E (TTM): -- 84.06 32.75
EPS (TTM): -0.23 -- --
ROI: -- 1.57 14.38
ROE: -- 2.43 16.07

BRIEF-Nymox Announces U.S. NDA For Fexapotide For BPH

* SAYS ‍RECENTLY HAD A PRE-NDA MEETING WITH FDA; NDA FOR FEXAPOTIDE FOR BPH​ WILL BE SUBMITTED LATER IN 2018 Source text for Eikon: Further company coverage:

05 Feb 2018

BRIEF-Nymox Reports 5-Yr Results From Prostate Cancer Study Of Fexapotide Triflutate In 146 U.S. Men

* NYMOX REPORTS 5-YEAR RESULTS FROM PROSPECTIVE RANDOMIZED CONTROLLED PROSTATE CANCER STUDY OF FEXAPOTIDE TRIFLUTATE IN 146 U.S. MEN

22 Jan 2018

Earnings vs. Estimates